Trevena: Jumps on plan to test drug for COVID-19 treatment

Trevena

02/06/2020 12:40

** Shares of biopharmaceutical co  TRVN.O  rise 15.79% to
$1.54 premarket
    ** Co to work with Imperial College London to evaluate if
its investigational new drug, TRV027, can be used to treat lung
injury and acute respiratory distress syndrome in COVID-19
patients  urn:newsml:reuters.com:*:nGNX2wmM08
    ** To study approximately 60 hospitalized, non-ventilated
patients older than 65 with confirmed or suspected COVID-19
infection - TRVN
    ** Up to last close, TRVN stock had risen 58.16%

 (Reporting by Vishwadha Chander in Bengaluru)
 ((Vishwadha.Chander@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 80 6749 6132;))